POZ - Treatment News : Treatment Failure: Symptoms Matter Too
Subscribe to:
POZ magazine E-newsletters
POZ Personals Sign In / Join
Username:
Password:

Back to home » Treatment News » April 2008

Special Reports

Rallying Behind HIV Vaccine Research

The Mother of All Battles

Face and Butt, Heal Thyselves

» More

Most Talked About

An HIV Doc's Dilemma (38)

Virtual Prevention: Fighting HIV Online (26)

HIV-Positive Man Sentenced to 35 Years for Spitting (20)

Face and Butt, Heal Thyselves (15)

Lambda Legal Responds to HIV Spitting Conviction (15)

Most Popular Lessons

Herpes Simplex Virus

Syphilis & Neurosyphilis

Shingles

The HIV Life Cycle

Human Papilloma Virus (HPV)

10 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailrssprint

April 25, 2008

Treatment Failure: Symptoms Matter Too

Symptoms of failing health are nearly as effective as viral loads or CD4 counts in determining if an antiretroviral (ARV) treatment regimen has stopped working and needs to be switched, according to new research published in The Lancet and reported by AIDSmap. These findings have important implications in developing countries, where shortages of viral load and CD4 tests are delaying the rollout of much needed ARV therapy. 

Using data from a number of cohort studies, Andrew Phillips, MD, of the Royal Free and University College Medical School in London, and his colleagues designed a computerized system to predict short- and long-term survival in people switching from a first to a second ARV regimen. They asked the system to predict survival if people switched following a viral load result above 500 copies, a CD4 drop of at least 50 percent from the highest measure after starting treatment, or based on a set of HIV-related symptoms maintained by the World Health Organization (WHO). Survival five years after a switch was 82 to 83 percent for each of the three models. It was only after 20 years where switching due to symptoms performed significantly less well than CD4 count or viral load.

The authors concede that computer simulations are not equal to clinical studies, and that their results stand in contrast to a clinical study conducted in Uganda in 2003 and 2004. However, they still conclude that these data support arguments favoring the distribution of ARV therapy in countries that do not have access to the viral load or CD4 tests that are typically used as a component of follow-up care in industrialized nations.

Search: CD4, viral load, Royal Free, Andrew, Phillips, Uganda, WHO


Scroll down to comment on this story.

emailrssprint

Name:

(2-50 characters)

Email:

(will not show)

City:

(optional)

Comment (500 characters left):

(Note: The POZ team review all comments before they are posted. Please do not include either ":" or "@" in your comment.)

| Posting Rules

Previous Comments:

         


[Go to top]

Get Started
Get Answers
What to do if you've just been diagnosed
How to find a support system
Things you should know before starting treatment
How to handle side effects and other concerns
How to tell someone you have HIV/AIDS

Talk to Us
Weekly Poll
Question: Do you suffer from allergies?
Yes
No

Monthly Poll
Question: Why are women being diagnosed so late that they have progressed to AIDS by the time of their diagnosis?
Women are too busy taking care of other family members
Doctors aren't testing
Doctors are unaware that a woman's symptoms can differ from a man's
Fear of HIV stigma
Denial
Women's lack of empowerment

Surveys
How do you see America's place in the global AIDS epidemic?

Tell us your political opinions on HIV/AIDS

more surveys  
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertise/contact us | site map]
© 2008 Smart + Strong. All Rights Reserved. Terms of use and Your privacy